4SC, ProQinase in cancer collaboration

4SC AG and fellow Germany company ProQinase GmbH have forged a research collaboration to identify a new generation of protein kinase inhibitors as the basis for the development of new anticancer drugs. Under the terms of the deal, ProQinase will provide disease-relevant PK targets, while 4SC will contribute its virtual high-throughput screening technology, 4SCan, and medicinal chemistry capabilities. The two firms will share rights to products arising from the alliance.